Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

txt4TKI: An Innovative Mobile Intervention to Improve Tyrosine Kinase Inhibitor Management Among Chronic Myeloid Leukemia Patients

NCT04694820 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT04694820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04694820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
txt4TKI: An Innovative Mobile Intervention to Improve Tyrosine Kinase Inhibitor Management Among Chronic Myeloid Leukemia Patients
Lead sponsor
Thomas Jefferson University
Phase
Not applicable
Overall status
Completed
Start date
June 5, 2020
Completion date
April 8, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia, bcr-abl1 positive, chronic phase chronic myelogenous leukemia